| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Revenue | 159 | |||
| Cost of sales | 64 | |||
| Gross profit | 95 | |||
| Research and development costs | 20,544 | |||
| General and administrative expenses | 5,795 | |||
| Restructuring charges | 0 | |||
| Operating loss | -26,244 | |||
| Foreign currency gain/(loss), net | 1,934 | |||
| Other income, net | 770 | |||
| Benefit from r&d credit | 2,583 | |||
| Loss before income tax expense | -20,957 | |||
| Income tax expense | 1 | |||
| Net loss | -20,958 | |||
| Earnings per share, basic | -0.15 | |||
| Earnings per share, diluted | -0.15 | |||
| Weighted average number of shares outstanding, basic | 141,701,848 | |||
| Weighted average number of shares outstanding, diluted | 141,701,848 | |||
Silence Therapeutics plc (SLNCF)
Silence Therapeutics plc (SLNCF)